2022
Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis
Lansky AJ, Tirziu D, Moses JW, Pietras C, Ohman EM, O'Neill WW, Ekono MM, Grines CL, Parise H. Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. The American Journal Of Cardiology 2022, 185: 29-36. PMID: 36210212, DOI: 10.1016/j.amjcard.2022.08.032.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionIntra-aortic balloon pumpPercutaneous coronary interventionAcute kidney injuryCardiogenic shockMyocardial infarctionIABP supportKidney injuryBalloon pumpImproved survivalPropensity adjustmentAcute ST-elevation myocardial infarctionST-elevation myocardial infarctionIndex hospitalization lengthLess myocardial infarctionPremier Healthcare DatabaseHospital myocardial infarctionPropensity-adjusted analysisMechanical circulatory supportMechanical support devicesImpella useHospital survivalIndex hospitalizationCoronary interventionReal-world practice
2013
Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial
Brener S, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink J, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson C, Stone G. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. American Heart Journal 2013, 166: 64-70. PMID: 23816023, DOI: 10.1016/j.ahj.2013.03.029.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAntibodies, MonoclonalCardiac CatheterizationCoronary AngiographyCoronary StenosisCoronary VesselsElectrocardiographyFemaleHumansImmunoglobulin Fab FragmentsInjections, Intra-ArterialMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexSurvival RateThrombectomyTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionInfarct sizeMyocardial infarctionAnterior ST-segment elevation myocardial infarctionMyocardial blush grade 2/3Myocardial infarction flow 3Primary percutaneous coronary interventionINFUSE-AMI trialMyocardial Infarction trialPrimary end pointST-segment resolutionPercutaneous coronary interventionSeptal perforator branchExtent of myocardiumEffect of ICSBivalirudin anticoagulationBolus abciximabFinal ThrombolysisIntracoronary abciximabKillip classLAD infarctsReperfusion therapyArtery occlusionCoronary intervention
2012
Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial
Stone G, Clayton T, Mehran R, Dangas G, Parise H, Fahy M, Pocock S. Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal 2012, 163: 522-529. PMID: 22424026, DOI: 10.1016/j.ahj.2011.11.016.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionAcute coronary syndromeBlood cell transfusionMajor bleedingRBC transfusionCell transfusionCoronary syndromeCardiac surgerySubsequent mortalityUrgent Intervention Triage Strategy (ACUITY) trialAllogeneic blood product transfusionInternational prospective trialsCoronary artery bypassMajor hemorrhagic complicationsOne-year mortalityBlood product transfusionCovariate-adjusted Cox modelsPrior retrospective studiesFresh frozen plasmaAcute CatheterizationArtery bypassHemorrhagic complicationsProduct transfusionHospital dischargeProspective trial
2002
Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience
Wilson P, D'Agostino R, Sullivan L, Parise H, Kannel W. Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience. JAMA Internal Medicine 2002, 162: 1867-1872. PMID: 12196085, DOI: 10.1001/archinte.162.16.1867.Peer-Reviewed Original ResearchConceptsAge-adjusted relative riskBody mass indexCoronary heart diseasePopulation attributable riskRelative riskCardiovascular diseaseCardiovascular sequelaeAngina pectorisExcess weightAttributable riskHeart diseaseOverweight statusRisk factorsCardiovascular disease risk factorsHighest population-attributable riskNew cardiovascular diseaseDisease risk factorsFramingham Heart Study participantsNormal-weight personsDisease end pointsNew hypertensionCardiovascular riskDiabetes mellitusPrimary outcomeMass index